Topic:

M&A

Latest Headlines

Latest Headlines

UPDATED: Shire nabs NPS's rare disease drug portfolio in $5.2B buyout

Shire has struck a deal to buy NPS Pharma and its rare disease drug portfolio for $46 a share, or $5.2 billion, making headlines for its go-it-alone strategy on the eve of the big JP Morgan conference in San Francisco.

AMRI spends $60M to beef up its manufacturing heft

AMRI, on the mend after a rough quarter, is laying out $60 million to expand its manufacturing footprint, agreeing to buy a couple of outposts from service provider Aptuit.

WuXi buys big into genomics with NextCODE deal

Chinese CRO giant WuXi PharmaTech is continuing its push into genomic sequencing, paying $65 million for NextCODE Health, a Big Data-focused spinout of the high-profile deCODE.

Valeant's still in the deal hunt, but it can grow 10%-plus without them, CEO says

Last month, rumors swirled that serial buyer Valeant would be swearing off its modus operandi for a little while to focus on cutting down debt in the wake of its Allergan bid failure. But according to CEO J. Michael Pearson, those who expect Valeant to stray from its dealmaking ways have another thing coming.

Analysts expect M&A frenzy to continue with deals by Pfizer, AbbVie, Valeant likely in 2015

Pharma M&A in 2014 hit a record-breaking $234 billion in announced acquisitions. Actavis led the pack with its $66 billion bid for Botox maker Allergan and $25 billion buyout of Forest Laboratories. But investors and analysts say 2015 could generate as many or more deals, with Pfizer, Valeant Pharmaceuticals, AbbVie and Shire expected to be in the mix.

Medtronic and Covidien win shareholder approval for proposed $43B merger

Medtronic and Covidien are nearing the finish line of their pending $43 billion merger as Medtronic shareholders voted on Tuesday to approve the deal, following in the footsteps of a similar vote from Covidien shareholders. 

Cardio3 dives into CAR-T with $180M Celdara deal

Cardio3 BioSciences is buying the cancer division of Celdara Medical, trading $10 million up front and promising more in exchange for a seat at the immuno-oncology table. 

Med tech exits pick up in 2014, momentum to continue into 2015

Venture-backed medical device and diagnostics companies are benefiting from a groundswell of investor interest in life sciences that has been spearheaded by great biotech returns for the last several years.

NPS is officially up for sale. Will deal-minded Shire bid?

After months of takeover speculation, New Jersey's NPS Pharmaceuticals is officially up for grabs. And now, all eyes are on rumored suitor Shire.

With Swiss pickup, Pfizer adds CMV candidate to growing vaccines unit

After 2014's growth spurt, Pfizer's vaccines unit is not done expanding. The pharma giant has grabbed privately held Swiss company Redvax for an undisclosed sum, adding a preclinical human cytomegalovirus (CMV) vaccine candidate and a tech platform and IP related to a second, undisclosed vaccine program.